AMEX · Financial Statements

Protalix BioTherapeutics, Inc. (PLX) Revenue, Earnings & Financial Statements

$2.88 AMEX: PLX Market Cap $242.84M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Protalix BioTherapeutics, Inc. most recently reported annual revenue of $53.0M, a net loss of $7.0M. Revenue declined at an average annual rate of 3.4% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Protalix BioTherapeutics, Inc.: Revenue rose from $9.0M in 2016 to $53.0M in 2025, a change of +488.9% over 9 years; net profit was positive in 2 of 10 reported years; operating margin moved from -360.5% to -10.4%, a shift of +350.1 percentage points; the most recent year shows a net loss of $7.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$9.0M$21.0M$34.0M$55.0M$63.0M$38.0M$48.0M$65.0M$53.0M$53.0M
Operating Expenses$42.0M$56.0M$54.0M$65.0M$60.0M$59.0M$61.0M$55.0M$49.0M$58.0M
Operating Profit−$33.0M−$35.0M−$19.0M−$11.0M$3.0M−$20.0M−$13.0M$10.0M$4.0M−$5.0M
Operating Margin-360.5%-163.8%-56.4%-19.6%4.3%-53.4%-27.3%16.0%7.3%-10.4%
Other Income$4.0M−$49.0M−$7.0M−$8.0M−$9.0M−$7.0M−$1.0M−$2.0M$0$0
Interest$4.0M$10.0M$8.0M$8.0M$10.0M$8.0M$3.0M$3.0M$1.0M$1.0M
Depreciation$2.0M$2.0M$2.0M$2.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax−$29.0M−$83.0M−$26.0M−$18.0M−$7.0M−$28.0M−$14.0M$9.0M$4.0M−$6.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%-3.7%3.0%29.4%-17.8%
Net Profit−$29.0M−$83.0M−$26.0M−$18.0M−$7.0M−$28.0M−$15.0M$8.0M$3.0M−$7.0M
EPS−$0.29−$6.50−$1.80−$1.23−$0.22−$0.62−$0.31$0.10$0.04−$0.08

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$10.0M$4.0M$13.0M$18.0M$18.0M$10.0M$16.0M$18.0M$9.0M$34.0M$20.0M$22.0M
Operating Expenses$16.0M$9.0M$16.0M$14.0M$11.0M$14.0M$14.0M$16.0M$14.0M$13.0M$15.0M$18.0M
Operating Profit−$6.0M−$5.0M−$2.0M$4.0M$7.0M−$4.0M$1.0M$2.0M−$5.0M$21.0M$5.0M$4.0M
Operating Margin-53.5%-129.6%-18.0%22.2%39.6%-41.0%7.5%11.9%-51.1%62.6%23.5%18.5%
Interest$1.0M$0$0$0$0$0$1.0M$0$0$0$0$0
Profit Before Tax−$6.0M−$5.0M−$2.0M$4.0M$7.0M−$4.0M$1.0M$2.0M−$5.0M$21.0M$5.0M$5.0M
Tax rate (%)5.9%2.9%3.0%15.8%11.2%3.0%75.2%-5.2%-15.2%13.4%22.3%14.3%
Net Profit−$6.0M−$5.0M−$2.0M$3.0M$6.0M−$4.0M$0$2.0M−$6.0M$18.0M$4.0M$4.0M
EPS−$0.08−$0.06−$0.03$0.03$0.09−$0.05$0.00$0.03−$0.07$0.22$0.05$0.05

Over the 10 years reported for Protalix BioTherapeutics, Inc., borrowings decreased from $78.0M in 2016 to $8.0M in 2025, cash stood at $15.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.48 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$82.0M$72.0M$61.0M$45.0M$68.0M$74.0M$56.0M$84.0M$73.0M$82.0M
Current Assets$72.0M$63.0M$53.0M$32.0M$56.0M$62.0M$45.0M$70.0M$60.0M$67.0M
Cash$63.0M$51.0M$38.0M$18.0M$18.0M$39.0M$17.0M$24.0M$20.0M$15.0M
Inventory$5.0M$8.0M$9.0M$8.0M$13.0M$18.0M$17.0M$19.0M$21.0M$26.0M
Receivables$1.0M$2.0M$5.0M$5.0M$2.0M$3.0M$5.0M$5.0M$3.0M$9.0M
Fixed Assets$9.0M$8.0M$6.0M$11.0M$10.0M$10.0M$10.0M$11.0M$10.0M$13.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$20.0M$0$5.0M$21.0M$15.0M$16.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$92.0M$104.0M$114.0M$116.0M$95.0M$80.0M$66.0M$51.0M$30.0M$34.0M
Current Liabilities$66.0M$23.0M$25.0M$40.0M$86.0M$33.0M$32.0M$46.0M$26.0M$27.0M
Borrowings$78.0M$52.0M$48.0M$61.0M$64.0M$33.0M$33.0M$28.0M$6.0M$8.0M
Other Liabilities$15.0M$51.0M$66.0M$55.0M$31.0M$46.0M$33.0M$23.0M$25.0M$26.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves−$10.0M−$31.0M−$53.0M−$70.0M−$27.0M−$6.0M−$11.0M$34.0M$43.0M$48.0M

For Protalix BioTherapeutics, Inc., operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $14.0M; free cash flow was positive in 1 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$32.0M−$10.0M−$8.0M−$19.0M−$26.0M−$10.0M−$25.0M−$1.0M$9.0M−$12.0M
Investing Cash Flow−$2.0M−$2.0M−$1.0M−$2.0M−$21.0M$17.0M−$6.0M−$18.0M$3.0M−$4.0M
Financing Cash Flow$0$0$0$0$0$0$0$1.0M$0$0
Net Cash Flow−$13.0M−$12.0M−$13.0M−$20.0M$0$21.0M−$22.0M$7.0M−$4.0M−$4.0M
Free Cash Flow−$33.0M−$11.0M−$8.0M−$20.0M−$27.0M−$12.0M−$26.0M−$2.0M$7.0M−$14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA8.55
FCF Yield5.86%
Quick Ratio2.14
Interest Coverage23.04
Return 1Y60.32%
Return 3Y116.43%
Return 5Y206.06%

Protalix BioTherapeutics, Inc. (PLX) financials — frequently asked questions

What is Protalix BioTherapeutics, Inc.'s annual revenue?

Protalix BioTherapeutics, Inc. (PLX) reported annual revenue of $53.0M in its most recent fiscal year.

What is Protalix BioTherapeutics, Inc.'s net profit?

Protalix BioTherapeutics, Inc. (PLX) reported a net loss of $7.0M in its most recent fiscal year.

What is PLX EV/EBITDA?

Protalix BioTherapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 8.55.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
PLX Overview PLX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.